SubHero Banner

Jemperli (dostarlimab-gxly) – Updated indication

February 10, 2023 - GSK announced that the FDA granted full approval to Jemperli (dostarlimab-gxly), for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer, as determined by an FDA-approved test, that has progressed on or following prior treatment with a platinum-containing regimen in any setting and are not candidates for curative surgery or radiation.

Download PDF